Sponsored Links 
Buy 3SBio Up to $10
3SBio Inc. (SSRX - Snapshot Report) is a China-based biotech company focused on developing and marketing therapeutics for nephrology, oncology and cancer supportive care. The company's flagship product EPIAO is the number 1 brand in China's EPO [erythropoietin] market.
Its second lead product TPIAO has gained rapid physician acceptance for thrombocytopenia and is making a meaningful contribution to the company's top line growth. Recent deal with US-based AMAG Pharmaceuticals Inc. (AMAG - Analyst Report) will boost its expansion into IV Iron market.
We believe shares of 3SBio are undervalued and are attractive at current levels. We maintain a Buy rating with a price target of $10.
 |
 |
 Share |
 RSS |
 Rate Pos |
 Rate Neg |
 Comment |
|
|
||||||
Loading Stories...Related Content
Loading Stories...Most Popular on Zacks.com
1.21 %
More Zacks Resources
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
More Zacks Links
| Market Summary | Nov 08, 2009 08:44 am ET |
Sponsored Links
[CLICK TO CLOSE X]